首页> 外文期刊>Cardiology and Cardiovascular Research >A Randomized Study Comparing Patency of Infarction Related Vessel at Time of Primary PCI in Patients Who Received Streptokinase and Who Did Not
【24h】

A Randomized Study Comparing Patency of Infarction Related Vessel at Time of Primary PCI in Patients Who Received Streptokinase and Who Did Not

机译:在接受链激酶的患者中对初级PCI时代梗死相关血管的通畅性的随机研究比较了梗塞相关血管

获取原文
       

摘要

oronary blood flow in an infarct related artery (IRA) in patients that had streptokinase (SK), as the fibrinolytic of choice before percutaneous intervention (PCI), in comparison to the blood flow in patients that underwent primary percutaneous intervention (PPCI) has not been well understood or considered for studies in recent times. All patients presenting with STEMI diagnosis within less than 12 hours from diagnosis either at the centre or referred to the center after SK were screened. 200 patients were randomized into primary PCI (PPCI) or pharmacoinvasive PCI following SK (PhI-SK) administration 3-24 hours after SK. Failed SK patients underwent rescue PCI immediately. The outcome of IRA patency pre- and post PCI in both groups along with short term outcome of bleeding, re-infarction or cardiovascular death in 30 days were looked at. The end points were reached in 81 of 89 (91.0%) in the SK group and 21 of 98 (21.4%) in the PPCI group (p-value 0.001), while TIMI 3 flow was seen in 87 of 89 (98.7%) patients post PCI in the SK group and 69 of 98 (70.4%) patients of PPCI (p-value 0.001). The outcomes of bleeding, MI and death were not different among the groups. We concluded that Fibrinolysis with SK is a viable and safe reperfusion strategy in STEMI especially in low- and middle-income countries (LMICs), where PPCI is not commonly available within the guideline recommended time. It can reduce stress and risk of complications that can occur during PPCI. There is no any difference in the early outcomes of bleeding, MI and death between the two groups.
机译:在具有链孢菌素(SK)的患者中,在梗死相关动脉(IRA)中的原始血流,作为经皮干预(PCI)之前选择的纤维蛋白溶解,与患者的血流相比,经过一次经皮干预(PPCI)没有在近来,已经很好地理解或考虑进行研究。所有患者均以在诊断到中心的诊断不到12小时内,筛选出SK后,筛选均匀的诊断。在SK后3-24小时后,将200名患者随机分为原发性PCI(PPCI)或药物血管吡啶虫PCI。失败的SK患者立即接受救援PCI。两组的IRA PATEND先前和PCI后的结果以及30天内出血,再梗塞或心血管死亡的短期结果。在SK组的81个(91.0%)中达到终点,PPCI组中的21例(p值<0.001),在87例中观察到21个(p值<0.001),而第89号次(98.7) %)PCI在SK组和98例(70.4%)PPCI患者中的患者(p值<0.001)。在群体中出血,MI和死亡的结果并不不同。我们得出结论,SK的纤维蛋白溶解是Stemi的可行性和安全的再灌注策略,特别是在低收入和中等收入国家(LMIC),其中PPCI在指南推荐时间内不常用。它可以减少在PPCI期间可能发生的压力和并发症的风险。两组之间出血,MI和死亡的早期结果没有任何差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号